Literature DB >> 26806610

Influenza Virus Shedding in Laninamivir-Treated Children upon Returning to School.

Hiroki Kondo1, Yugo Shobugawa, Akinobu Hibino, Ren Yagami, Clyde Dapat, Minoru Okazaki, Taketo Otsuka, Koyata Fujii, Mohd Rohaizat Hassan, Reiko Saito.   

Abstract

The current School Health and Safety Act in Japan states that children with influenza infection should stay home until day 6(th) after symptoms onset. This was an amendment of a previous version recommending school return on day 3 after defervescence. Here, we investigated the duration of fever and virus shedding after laninamivir treatment in 7 children infected with influenza A(H3N2) virus and 21 children with influenza B virus in relation to the school return timing recommended by the School Health and Safety Act during the 2011-2012 influenza season. Nasal discharge was collected on the first, second, and third hospital visits and virus titers were assessed by virus culture and real-time PCR. Duration of fever after laninamivir treatment was 1 day longer for influenza B than for influenza A(H3N2). Virus detection rates with 50% tissue culture infectious dose and viral RNA were highest at the first visit and gradually decreased at subsequent visits. Virus positivity rates were detectable at the time of defervescence in less than half of the enrolled patients (14.3-42.9%). Virus shedding rates were similarly low (0.0-19.0%) on day 3 or later from defervescence and on day 6 or later from fever onset (school return dates per the old and current School Health and Safety Act) regardless of the influenza type. In conclusion, despite the higher efficacy of laninamivir against A(H3N2) viruses than B viruses, viral shedding is low after return to school for both types, regardless of the version of the School Health and Safety Act.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26806610     DOI: 10.1620/tjem.238.113

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  6 in total

Review 1.  Japanese Surveillance Systems and Treatment for Influenza.

Authors:  Hassan Zaraket; Reiko Saito
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-10

2.  Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.

Authors:  Keiichi Taniguchi; Yoshinori Ando; Haruaki Nobori; Shinsuke Toba; Takeshi Noshi; Masanori Kobayashi; Makoto Kawai; Ryu Yoshida; Akihiko Sato; Takao Shishido; Akira Naito; Keita Matsuno; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

3.  Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.

Authors:  Momoko Mawatari; Reiko Saito; Akinobu Hibino; Hiroki Kondo; Ren Yagami; Takashi Odagiri; Ikumi Tanabe; Yugo Shobugawa
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

4.  A 1-year cross-sectional study on the predominance of influenza among hospitalized children in a tropical area, Kota Kinabalu, Sabah.

Authors:  Kai Joo Lim; Jecelyn Leaslie John; Syed Sharizman Syed Abdul Rahim; Richard Avoi; Mohd Rohaizat Hassan; Mohammad Saffree Jeffree; Mohd Yusof Ibrahim; Kamruddin Ahmed
Journal:  J Physiol Anthropol       Date:  2022-04-02       Impact factor: 2.867

5.  Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.

Authors:  Hiroki Koshimichi; Toru Ishibashi; Nao Kawaguchi; Chisako Sato; Akira Kawasaki; Toshihiro Wajima
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

6.  Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015-2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation.

Authors:  Irina Chon; Reiko Saito; Akinobu Hibino; Ren Yagami; Clyde Dapat; Takashi Odagiri; Hiroki Kondo; Isamu Sato; Shinji Kimura; Takashi Kawashima; Naoki Kodo; Hironori Masaki; Norichika Asoh; Yoshiko Tsuchihashi; Hassan Zaraket; Yugo Shobugawa
Journal:  Vaccine X       Date:  2019-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.